PRRUF
Price
$0.19
Change
-$0.02 (-9.52%)
Updated
May 29 closing price
Capitalization
228.68M
XFOR
Price
$1.83
Change
-$0.17 (-8.50%)
Updated
Jun 27 closing price
Capitalization
13.14M
31 days until earnings call
Interact to see
Advertisement

PRRUF vs XFOR

Header iconPRRUF vs XFOR Comparison
Open Charts PRRUF vs XFORBanner chart's image
Immutep
Price$0.19
Change-$0.02 (-9.52%)
Volume$600
Capitalization228.68M
X4 Pharmaceuticals
Price$1.83
Change-$0.17 (-8.50%)
Volume$966.5K
Capitalization13.14M
PRRUF vs XFOR Comparison Chart in %
Loading...
PRRUF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRRUF vs. XFOR commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRRUF is a Hold and XFOR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (PRRUF: $0.19 vs. XFOR: $1.83)
Brand notoriety: PRRUF and XFOR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRRUF: 32% vs. XFOR: 339%
Market capitalization -- PRRUF: $228.68M vs. XFOR: $13.14M
PRRUF [@Biotechnology] is valued at $228.68M. XFOR’s [@Biotechnology] market capitalization is $13.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRRUF’s FA Score shows that 0 FA rating(s) are green whileXFOR’s FA Score has 2 green FA rating(s).

  • PRRUF’s FA Score: 0 green, 5 red.
  • XFOR’s FA Score: 2 green, 3 red.
According to our system of comparison, XFOR is a better buy in the long-term than PRRUF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRRUF’s TA Score shows that 4 TA indicator(s) are bullish while XFOR’s TA Score has 3 bullish TA indicator(s).

  • PRRUF’s TA Score: 4 bullish, 3 bearish.
  • XFOR’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, PRRUF is a better buy in the short-term than XFOR.

Price Growth

PRRUF (@Biotechnology) experienced а 0.00% price change this week, while XFOR (@Biotechnology) price change was -31.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

XFOR is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRRUF($229M) has a higher market cap than XFOR($13.1M). PRRUF YTD gains are higher at: -4.879 vs. XFOR (-91.685). XFOR has higher annual earnings (EBITDA): 25.2M vs. PRRUF (-43.83M). PRRUF has more cash in the bank: 159M vs. XFOR (87M). PRRUF has less debt than XFOR: PRRUF (1.69M) vs XFOR (78M). XFOR has higher revenues than PRRUF: XFOR (31.4M) vs PRRUF (0).
PRRUFXFORPRRUF / XFOR
Capitalization229M13.1M1,748%
EBITDA-43.83M25.2M-174%
Gain YTD-4.879-91.6855%
P/E RatioN/A0.87-
Revenue031.4M-
Total Cash159M87M183%
Total Debt1.69M78M2%
FUNDAMENTALS RATINGS
PRRUF vs XFOR: Fundamental Ratings
PRRUF
XFOR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
17
Undervalued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
9612
PRICE GROWTH RATING
1..100
6198
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XFOR's Valuation (17) in the Biotechnology industry is significantly better than the same rating for PRRUF (85) in the null industry. This means that XFOR’s stock grew significantly faster than PRRUF’s over the last 12 months.

PRRUF's Profit vs Risk Rating (83) in the null industry is in the same range as XFOR (100) in the Biotechnology industry. This means that PRRUF’s stock grew similarly to XFOR’s over the last 12 months.

XFOR's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for PRRUF (96) in the null industry. This means that XFOR’s stock grew significantly faster than PRRUF’s over the last 12 months.

PRRUF's Price Growth Rating (61) in the null industry is somewhat better than the same rating for XFOR (98) in the Biotechnology industry. This means that PRRUF’s stock grew somewhat faster than XFOR’s over the last 12 months.

PRRUF's P/E Growth Rating (100) in the null industry is in the same range as XFOR (100) in the Biotechnology industry. This means that PRRUF’s stock grew similarly to XFOR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRRUFXFOR
RSI
ODDS (%)
Bullish Trend 3 days ago
59%
Bullish Trend 3 days ago
89%
Stochastic
ODDS (%)
N/A
Bullish Trend 3 days ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
54%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
47%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 12 days ago
80%
Declines
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
43%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PRRUF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NPK97.920.61
+0.63%
National Presto Industries
NWE50.85-0.32
-0.63%
NorthWestern Energy Group
RCI29.08-0.25
-0.85%
Rogers Communications
REBN2.52-0.07
-2.51%
Reborn Coffee
BDTX2.36-0.10
-4.07%
Black Diamond Therapeutics

PRRUF and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRRUF has been loosely correlated with IMMP. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRRUF jumps, then IMMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRRUF
1D Price
Change %
PRRUF100%
N/A
IMMP - PRRUF
40%
Loosely correlated
N/A
SAVA - PRRUF
33%
Loosely correlated
-3.28%
ELTX - PRRUF
27%
Poorly correlated
N/A
CALC - PRRUF
27%
Poorly correlated
N/A
XFOR - PRRUF
25%
Poorly correlated
-8.50%
More

XFOR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XFOR has been loosely correlated with ABP. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if XFOR jumps, then ABP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XFOR
1D Price
Change %
XFOR100%
-8.50%
ABP - XFOR
50%
Loosely correlated
-5.38%
HOFBF - XFOR
35%
Loosely correlated
N/A
CRDF - XFOR
32%
Poorly correlated
-0.32%
INM - XFOR
32%
Poorly correlated
-2.31%
ABSI - XFOR
31%
Poorly correlated
-3.32%
More